NL-OMON50424已完成4 期
REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial) - REBACARE TRIA
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •- Patients with histologically proven urothelial carcinoma of the UUT with or
- •without concurrent carcinoma in situ (CIS only is also allowed) or patients
- •with a suspicion of a urothelial carcinoma of the UUT on CTscan with or without
- •a urinary cytology sample suspicious of the presence of high-grade urothelial
- •carcinoma. In case urinary cytology shows no abnormality and no diagnostic URS
- •is done, conclusive results of the CT-urography are sufficient for inclusion
- •and the coordinating
- •investigator will evaluate the eligibility of the subject in consultation with
- •the local investigator.
- •- Patients treated either by partial ureterectomy or by a radical
- •nephro-ureterectomy (open or laparoscopic) including a bladder cuff.
- •- Age >= 18 years.
- •- WHO performance status 0,1, or 2.
- •- Negative pregnancy test in women with childbearing potential.
- •- Written informed consent.
排除标准
- •- If pre-operative histology obtained by biopsy: aberrant histology of the UUT
- •tumor of >50% (adenocarcinoma, small cell carcinoma, squamous cell
- •carcinoma).
- •- Postoperative pathological report shows absence of tumor (pT0) or >50% of the
- •UUT tumor shows aberrant histology.
- •- History or presence of a malignant tumor or carcinoma in situ of the bladder.
- •- History of UUT urothelial carcinoma on the contralateral side or presence of
- •bilateral UUT urothelial carcinoma.
- •- Known allergy against Mitomycin.
- •- Anticipated adjuvant intravesical treatment with chemo- or immunotherapy.
- •- Anticipated adjuvant intravesical treatment with chemo- or immunotherapy
- •following a diagnostic URS.
- •- Acute urinary tract infection at the time of inclusion as assessed by urinary
- •- Lymphadenopathy or distant metastases as assessed by preoperative CT-scan of
- •thorax and abdomen.
- •- Any other concurrent severe or uncontrolled disease preventing the safe
- •administration of intravesical Mitomycin.
- •- Breastfeeding women.
研究者
相似试验
进行中(未招募)
1 期
REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial)pper Tract Urothelial Carcinoma (UTUC).MedDRA version: 20.0Level: HLGTClassification code 10038364Term: Renal and urinary tract neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10038365Term: Renal and urinary tract therapeutic proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2017-000949-53-NLErasmus MC, Dept. Urology190
招募中
不适用
To investigate whether rinsing the bladder with chemotherapy right before an operation that removes the kidney and ureter because of a malignant tumor is effective to reduce the risk of a subsequent bladder tumorNL-OMON24959Erasmus university Medical Center170
已完成
2 期
Pilot study of nab-Paclitaxel in combination with capecitabine as second line treatment of advanced biliary cancer.advanced biliary cancerCancer - Biliary tree (gall bladder and bile duct)ACTRN12615000504516Illawarra and Shoalhaven Local Health District10
招募中
4 期
Prevention and Treatment of Recurrence and Metastasis of Hepatocellular Carcinoma after Operation with Ganyanshu DecoctionsHepatocellular CarcinomaITMCTR2000003577onghua Hospital, Shanghai University of Traditional Chinese Medicine
已完成
不适用
BLANKET: Treating fear of cancer recurrence in primary careNL-OMON49012Helen Dowling Instituut235
